Loading
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Latest quote
$1.54
+$0.09 · +6.21%
After-hours
$1.54
$0.00 · 0.00%
Oct 9, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Day range
Current $1.54
52-week range
Current $1.54
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
58
Fair Value
Sentiment
69
Bullish
Risk
64
High Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Day range
Current $1.54
52-week range
Current $1.54
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 250K USD | — | — |
| Gross profit | — | — | 250K USD | — | — |
| Research and development | 10.19M USD | 9.06M USD | 6.89M USD | 6.55M USD | 2.43M USD |
| Selling, general, and administrative | 7.86M USD | 5.8M USD | 6.2M USD | 8.76M USD | 9.31M USD |
| Operating expenses | 18.06M USD | 14.86M USD | 13.32M USD | 15.72M USD | 41.85M USD |
| Interest income | — | — | — | 13K USD | — |
| Interest expense | 10K USD | 12K USD | 15K USD | 13K USD | 2.4M USD |
| Depreciation and amortization | 3K USD | 3K USD | 4K USD | 3K USD | 2K USD |
| Operating income | −18.06M USD | −14.86M USD | −13.07M USD | −15.72M USD | −41.85M USD |
| Net income | −16.78M USD | −14.44M USD | −12.3M USD | −14.26M USD | −26.62M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.50
192.21% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 8, 2024 | 1:15 | — | — |
Stock split | Nov 16, 2022 | 1:50 | — | — |
Stock split | Apr 28, 2021 | 1:6 | — | — |
Stock split | Jul 18, 2019 | 1:20 | — | — |
Stock split | Jan 9, 2017 | 1:13 | — | — |
Effective Apr 8, 2024
1:15
Effective Nov 16, 2022
1:50
Effective Apr 28, 2021
1:6
Effective Jul 18, 2019
1:20
Effective Jan 9, 2017
1:13
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM5.94M0.01%77.7B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3.4M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN1.75M0.01%13.75B USD0.24%$210.87-0.04%
Vanguard Russell 2000 ETFVTWO1.65M0.01%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC703.8K0.05%1.32B USD0.60%$183+0.11%
Simplify Propel Opportunities ETFSURI629.78K0.84%74.99M USD2.82%$17.06-0.14%
iShares Core S&P Total U.S. Stock Market ETFITOT557.34K0.00%97.8B USD0.03%$169.66+0.64%
iShares Russell 2000 Growth ETFIWO355.92K0.00%14.04B USD0.24%$356.78+0.94%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIiShares Core S&P Total U.S. Stock Market ETFITOTiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
